Characterization of STZ-induced type 2 diabetes in Zucker fatty rats

Experimental Animals

Volumn 57, Issue 4, 2008, Pages 335-345

  Okamoto, Takashi ^a,b   Kanemoto, Naohide ^a   Ohbuchi, Yutaka ^a   Okano, Mai ^a   Fukui, Hiroyuki ^b   Sudo, Toshiki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Streptozotocin; Type 2 diabetes mellitus (T2DM); Zucker fatty rat

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; STREPTOZOCIN; GLYCOSYLATED HEMOGLOBIN; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RELEASE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; RAT; STREPTOZOCIN DIABETES; UPREGULATION; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; ZUCKER RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; LIPIDS; MALE; METABOLIC SYNDROME X; RATS; RATS, ZUCKER; STREPTOZOCIN;

EID: 51449118872     PISSN: 13411357     EISSN: None     Source Type: Journal    
DOI: 10.1538/expanim.57.335     Document Type: Article

References (26)

1. Boivin, A. and Deshaies, Y. 2000. Contribution of hyperinsulinemia to modulation of lipoprotein lipase activity in the obese Zucker rat. Metabolism 49: 134-140.
2. Clark, J.B., Palmer, C.J., and Shaw, W.N. 1983. The diabetic Zucker fatty rat. Proc. Soc. Exp. Biol. Med. 173: 68-75.
3. Defronzo, R.A., Bonadonna, R.C., and Ferrannini, E. 1992. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318-368.
4. Folch, J., Lees, M., and Sloane Stanley, G.H. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
5. Ganda, O.P., Rossini, A.A., and Like, A.A. 1976. Studies on streptozotocin diabetes. Diabetes 25: 595-603.
6. Henry, R.R. 2003. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin. Ther. 25: B47-B63.
7. Hori, M., Satoh, M., Furukawa, K., Sakamoto, Y., Hakamata, H., Komohara, Y., Takeya, M., Sasaki, Y., Miyazaki, A., and Horiuchi, S. 2004. Acyl-coenzyme A:Cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats. Arterioscler. Thromb. Vasc. Biol. 24: 1689-1695.
8. Hundal, H.S., Ramlal, T., Reyes, R., Leiter, L.A., and Klip, A. 1992. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 131: 1165-1173.
9. Iida, M., Murakami, T., Ishida, K., Mizuno, A., Kuwajima, M., and Shima, K. 1996. Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem. Biophys. Res. Commun. 222: 19-26.
10. Jornson, A.B., Webster, J.M., Sum, C.F., Heseltine, L., Argyraki, M., Cooper, B.G., and Taylor, R. 1993. The impact of metformin therapy on glucose production and skeletal muscle glycogen synthase activity in overweight type 2 diabetic patients. Metabolism 42: 1217-1222.
11. Junod, A., Lambert, A.E., Orci, L., Pictet, R., Gonet, A.E., and Renold, A.E. 1967. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 126: 201-205.
12. Kumano, S., Matsumoto, H., Takatsu, Y., Noguchi, J., Kitada, C., and Ohtaki, T. 2003. Changes in hypothalamic expression levels of Galanin-like peptide in rat and mouse models support that it is a Leptin-target peptide. Endocrinology 144: 2634-2643.
13. Kusunoki, J., Aragane, K., Kitamine, T., Kozono, H., Kano, K., Fujinami, K., Kojima, K., Chiwata, T., and Sekine, Y. 2000. Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity. Arterioscler. Thromb. Vasc. Biol. 20: 171-178.
14. Lebovintz, H.E. and Banerji, M.A. 2004. Treatment of insulin resistance in diabetes mellitus. Eur. J. Pharmacol. 490: 135-146.
15. Liu, Y.Q., Jetton, T.L., and Leahy, J.L. 2002. Beta-cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J. Biol. Chem. 277: 39163-39168.
16. fa allele of the Zucker fatty rat into nonobese Spontaneously Diabetic Torii (SDT) rats. Exp. Anim. 54: 13-20.
17. Masuyama, T., Komeda, K., Hara, A., Noda, M., Shinohara, M., Oikawa, T., Kanazawa, Y., and Taniguchi, K. 2004. Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats. Biochem. Biophys. Res. Commun. 314: 870-877.
18. Natali, A. and Ferrannini, E. 2006. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologica 49:431-441.
19. Nolan, C.J., Leahy, U., Delghingaro-Augusto, J., Moibi, J., Soni, K., Peyot, M.-L., Fortier, M., Guay, C., Lamontagne, J., Barbeau, A., Przybytkowski, E., Joly, E., Masiello, P., Wang, S., Mitchell, G.A., and Prentki, M. 2006. Beta cell compensation for insulin resistance in Zucker fatty rats: increased lypolysis and fatty acid signaling. Diabetologia 49: 2120-2130.
20. Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., and Polonsky, K.S. 1998. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47: 358-364.
21. Reed, M.J., Meszaros, K., Entes, L.J., Pinkett, J.G., Gadbois, T.M., and Reaven, G.M. 2000. A new model rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49: 1390-1394.
22. Srinvansan, K., Viswanad, B., Asrat, L., Kaul, C.L., and Ramarao, P. 2005. Combination of high fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and parmacological screening. Pharmacol. Res. 52: 313-320.
23. Szkudelski, T. 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50: 537-546.
24. Tokuyama, Y., Sturis, J., DePaoli, A.M., Takeda, J., Stoffel, M., Tang, J., Sun, X., Polonsky, K.S., and Bell, G.I. 1995. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44: 1447-1457.
25. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., and Moller, D.E. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 109: 1167-1174.
26. Zimmet, P., Alberti, K.G., and Shaw, J. 2001. Global and societal implications of the diabetes epidemic. Nature 414: 782-787.